Fevipiprant

Phase 3Small molecule

Novartis

Fevipiprant is one of 30 small molecule programs targeting Nasal polyposis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasal PolyposisActive, not recruiting

AsthmaActive, not recruiting

Nasal PolyposisPhase 3

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Singulair

AstraZeneca

Preclinical

17 2

Fevipiprant

Novartis

Phase 3

1 3

Spiriva

Boehringer Ingelheim

Preclinical

8 4

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 5

Arcoxia

Symbicort

6 7

Atrovent

Boehringer Ingelheim

Preclinical

2 8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

1 9

Paracetamol

GSK

Preclinical

1 10

Aclidinium Bromide

AstraZeneca

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatic Impairment1 trial

Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects

Completed· Novartis logo

Novartis·Phase 1·NCT03048448·42 enrolled

Nasal polyposis1 trial

Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma

Completed· Novartis logo

Novartis·Phase 3·NCT03681093·98 enrolled

Asthma1 trial

Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma

Terminated· Novartis logo

Novartis·Phase 2·NCT03650400·11 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Fevipiprant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fevipiprant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fevipiprant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

Fevipiprant

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatic Impairment1 trial

Nasal polyposis1 trial

Asthma1 trial

References

Drug Info

Quick Facts

Related News